The FDA is currently developing a series of four Patient-Focused Drug Development (PFDD) Guidance Documents for the healthcare industry. This insight brief outlines PFDD Guidance 1 and 2, which are focused on ensuring that sponsors obtain robust, meaningful and interpretable patient input to understand their experience with their disease and its treatment to inform medical product development.
Clinical trials face increasing pressure to deliver new treatments to market faster. IQVIA Connected Devices accelerates trial outcomes with medical device recommendations that fit your clinical study, deliver cleaner data, and speed data collection and analysis with lower patient and site burdens.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
.svg){kind=icon}
